<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01191359</url>
  </required_header>
  <id_info>
    <org_study_id>SP-B-02</org_study_id>
    <nct_id>NCT01191359</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Two Different Administration Routes With SLITonePLUS Birch</brief_title>
  <official_title>A Multicentre Randomised Phase II Clinical Pilot Study to Compare the Pharmacodynamic Efficacy and Tolerability of the Sublingual and the Vestibular Administration Route for SLITonePLUS® Birch</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ALK-Abelló A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ALK-Abelló A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentre Phase II trial, comparing two different administration routes of SLITonePLUS
      Birch in regard to pharmacodynamic efficacy and tolerability.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamic efficacy of two different administration routes of SLITonePLUS Birch</measure>
    <time_frame>after 4, 8, 12, 24, 36 weeks of treatment</time_frame>
    <description>specific antibody determination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the two administration routes with regard to safety aspects</measure>
    <time_frame>36 weeks</time_frame>
    <description>adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Allergy</condition>
  <arm_group>
    <arm_group_label>sublingual administration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral immunotherapy with drops applied once daily by single dose containers (200 STU per dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vestibular administration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral immunotherapy with drops applied by single dose containers (200 STU per dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>oral immunotherapy</intervention_name>
    <description>orally applied specific immunotherapy</description>
    <arm_group_label>sublingual administration</arm_group_label>
    <arm_group_label>vestibular administration</arm_group_label>
    <other_name>SLITone birch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A history of Birch pollen allergy

          -  Positive skin prick test to birch

          -  Positive specific IgE to birch

        Exclusion criteria:

          -  Uncontrolled or severe asthma (FEV1&lt;70% of predicted value in spite of adequate
             pharmacologic treatment)

          -  Previous treatment by immunotherapy with birch or a cross-reactingtree pollen allergen
             within the previous 5 years

          -  Concomitant SLIT with any allergen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Bieber, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitäsklinik Bonn, Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinik Bonn, Dermatology</name>
      <address>
        <city>Bonn</city>
        <zip>D-53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2010</study_first_submitted>
  <study_first_submitted_qc>August 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2010</study_first_posted>
  <last_update_submitted>February 7, 2013</last_update_submitted>
  <last_update_submitted_qc>February 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

